Information Provided By:
Fly News Breaks for February 27, 2020
Feb 27, 2020 | 09:09 EDT
Roth Capital analyst Scott Henry lowered the firm's price target on RedHill Biopharma to $15 from $20.25 and keeps a Buy rating on the shares. Post the acquisition of Movantik, the analyst expects continuation of modest prescription declines for Movantik and targets minimal initial revenues for Aemcolo. Talicia remains the wildcard with the most variability, he argues, adding that he targets breakeven in 2021.
News For RDHL From the Last 2 Days
There are no results for your query RDHL